XOMA Corp (XOMA) - Financial and Strategic SWOT Analysis Review

XOMA Corp (XOMA) - Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH81739FSA
  • |
  • Pages: 51
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

XOMA Corp (XOMA)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

XOMA Corp (Xoma), formerly Xoma Ltd, is a biopharmaceutical company that develops antibody-based therapeutics. Its lead product, gevokizumab is a monoclonal antibody used for the treatment of a wide variety of inflammatory diseases and other diseases. Its other pipeline products include X358, X213 and X129. XOMA X358 is a human negative allosteric modulating insulin receptor antibody; X213 (formerly LFA 102) is an allosteric inhibitor of prolactin action; X129 is a potent fragment of a monoclonal antibody with negative allosteric modulation activity. Xoma has developed its proprietary antibody discovery, optimization and development technologies, comprising ADAPT, ModulX and OptimX. It operates through its subsidiaries in Bermuda, Ireland, and the US. Xoma is headquartered in Berkeley, California, the US.

XOMA Corp Key Recent Developments

Jun 26,2018: XOMA Added to the Russell 2000 and Russell 3000 Indexes

May 09,2018: XOMA Reports First Quarter 2018 Financial Results

May 08,2018: XOMA Announces USD20 Million Credit Facility with Silicon Valley Bank to Advance Royalty-Aggregator Business Model

Mar 07,2018: XOMA Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

Jan 08,2018: XOMA Strengthens Leadership Team with Appointments of Chief Business Officer and General Counsel

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

XOMA Corp-Key Facts 6

XOMA Corp-Key Employees 7

XOMA Corp-Key Employee Biographies 8

XOMA Corp-Major Products and Services 9

XOMA Corp-History 10

XOMA Corp-Company Statement 14

XOMA Corp-Locations And Subsidiaries 16

Head Office 16

Other Locations & Subsidiaries 16

Section 2-Company Analysis 17

Company Overview 17

XOMA Corp-Business Description 18

Geographical Segment: Asia Pacific 18

Performance 18

Geographical Segment: Europe 18

Performance 18

Geographical Segment: United States 19

Performance 19

XOMA Corp-Corporate Strategy 20

XOMA Corp-SWOT Analysis 21

SWOT Analysis-Overview 21

XOMA Corp-Strengths 21

XOMA Corp-Weaknesses 22

XOMA Corp-Opportunities 23

XOMA Corp-Threats 24

XOMA Corp-Key Competitors 25

Section 3-Company Financial Ratios 26

Financial Ratios-Capital Market Ratios 26

Financial Ratios-Annual Ratios 27

Performance Chart 29

Financial Performance 29

Financial Ratios-Interim Ratios 30

Financial Ratios-Ratio Charts 31

Section 4-Company's Lifesciences Financial Deals and Alliances 32

XOMA Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 32

XOMA Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 33

XOMA Corp, Recent Deals Summary 34

Section 5-Company's Recent Developments 35

Jun 26, 2018: XOMA Added to the Russell 2000 and Russell 3000 Indexes 35

May 09, 2018: XOMA Reports First Quarter 2018 Financial Results 36

May 08, 2018: XOMA Announces USD20 Million Credit Facility with Silicon Valley Bank to Advance Royalty-Aggregator Business Model 37

Mar 07, 2018: XOMA Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update 38

Jan 08, 2018: XOMA Strengthens Leadership Team with Appointments of Chief Business Officer and General Counsel 40

Nov 06, 2017: XOMA Reports Third Quarter 2017 Financial Results 41

Aug 08, 2017: XOMA Reports Second Quarter 2017 Financial Results 42

May 18, 2017: XOMA Earns USD10 Million Milestone Payment as Another of its Licensed Assets Advances into Clinical Development 43

May 09, 2017: XOMA Reports First Quarter 2017 Financial Results 44

Mar 16, 2017: XOMA Reports Fourth Quarter and Full Year 2016 Financial Results 45

Section 6-Appendix 47

Methodology 47

Ratio Definitions 47

About GlobalData 51

Contact Us 51

Disclaimer 51

List of Figures

XOMA Corp, Performance Chart (2013-2017) 29

XOMA Corp, Ratio Charts 31

XOMA Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 32

XOMA Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 33

List of Tables

XOMA Corp, Key Facts 6

XOMA Corp, Key Employees 7

XOMA Corp, Key Employee Biographies 8

XOMA Corp, Major Products and Services 9

XOMA Corp, History 10

XOMA Corp, Subsidiaries 16

XOMA Corp, Key Competitors 25

XOMA Corp, Ratios based on current share price 26

XOMA Corp, Annual Ratios 27

XOMA Corp, Annual Ratios (Cont...1) 28

XOMA Corp, Interim Ratios 30

XOMA Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 32

XOMA Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 33

XOMA Corp, Recent Deals Summary 34

Currency Codes 47

Capital Market Ratios 47

Equity Ratios 48

Profitability Ratios 48

Cost Ratios 49

Liquidity Ratios 49

Leverage Ratios 50

Efficiency Ratios 50

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Soligenix Inc

Lux Biosciences Inc

EyePoint Pharmaceuticals Inc

XOMA Corp, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license

Single User License
USD 125 INR 9065
Site License
USD 250 INR 18130
Corporate User License
USD 375 INR 27195

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com